Table 5.
Comparison of therapeutic effects between patients with BRII-196/BRII-198 treatment and those without
| SARS-CoV-2 nucleic acid negative conversion (days) | SARS-CoV-2 IgG antibody level when SARS-CoV-2 nucleic acid turned negative | ||
|---|---|---|---|
| BRII-196/BRII-198-treated group (n=30) | 17.37±5.05 | 78.73±48.40 | |
| Non-BRII-196/BRII-198-treated group (n=21) | 20.76±6.27 | 55.46±55.40 | |
| t | 2.139 | 1.592 | |
| P | 0.037 | 0.118 | |
| Ordinary | BRII-196/BRII-198-treated group (n=15) | 17.93±6.03 | 60.17±55.65 |
| Non-BRII-196/BRII-198-treated group (n=16) | 17.93±6.03 | 59.64±57.17 | |
| t | 0.856 | 0.026 | |
| P | 0.399 | 0.979 | |
| Severe | BRII-196/BRII-198-treated group (n=15) | 16.80±3.97 | 97.28±31.90 |
| Non-BRII-196/BRII-198-treated group (n=5) | 23.60±4.67 | 42.10±52.85 | |
| 3.185 | 2.843 | ||
| 0.005 | 0.011 | ||